Recommendation ID
IPG376/1
Question
NICE encourages further research into extracorporeal shockwave therapy (ESWT) for refractory greater trochanteric pain syndrome. Research studies should clearly describe patient selection, imaging, and treatment protocols. Outcomes should include functional and quality-of-life scores with at least 1 year of follow-up.
Any explanatory notes
(if applicable)
Evidence on the efficacy and safety of extracorporeal shockwave therapy (ESWT) for refractory greater trochanteric pain syndrome is limited in quality and quantity. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

Source guidance details

Comes from guidance
Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome
Number
IPG376
Date issued
January 2011

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No